Bank of America Names Five Must-Have Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 21 2026
0mins
Should l Buy EVR?
Source: CNBC
- Evercore Strong Performance: Evercore's recent quarterly earnings report showed strong top and bottom line beats, with analyst Ebrahim Poonawala noting that the firm's exposure to large-cap M&A and growth in non-M&A advisory revenues will support EPS growth, making it a compelling investment opportunity.
- Live Nation Growth Potential: Live Nation is viewed as a leader in global live entertainment, with analyst Peter Henderson highlighting robust demand and healthy consumer spending trends that will underpin its medium to long-term growth; despite regulatory pressures, the stock remains attractive, having risen 16% in the past month.
- Medline Market Leader: Analyst Andrew Obin initiated coverage of Medline with a buy rating, forecasting sustainable high-single digit organic growth driven by market share gains in the $175 billion U.S. market, with the stock up 13% over the past month.
- Waystar Steady Growth: Waystar is well-positioned for steady growth supported by stable end-market demand for revenue cycle management solutions, with analysts believing the company can expand relationships with 18 of the top 22 hospitals, driving further growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVR
Wall Street analysts forecast EVR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 336.350
Low
342.36
Averages
389.87
High
425.00
Current: 336.350
Low
342.36
Averages
389.87
High
425.00
About EVR
Evercore Inc. is an investment banking and investment management company. The Company's segment includes Investment Banking & Equities and Investment Management. Investment Banking & Equities includes the investment banking business through which it provides advice to clients on significant mergers, acquisitions, divestitures, shareholder activism, and other strategic corporate transactions, with a particular focus on advising multinational corporations and private equity firms on large, complex transactions. It also provides liability management and restructuring advice to companies in financial transition, as well as to creditors, shareholders, and potential acquirers. Investment Management includes the wealth management business, through which it provides investment advisory, wealth management and fiduciary services for high-net-worth individuals and associated entities, and the private equity business, which holds interests in private equity funds not managed by the Company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceutical Stock Doubles, Analysts Remain Optimistic
- Stock Price Surge: Teva Pharmaceutical's stock has soared over 100% in the past 12 months, reflecting strong market confidence in its recovery, with analysts generally optimistic about its future performance.
- Analyst Ratings Positive: In a survey by S&P Global, 12 out of 13 analysts rated Teva as a 'buy' or 'strong buy', indicating recognition of its potential 11% upside in the market.
- Significant Sales Growth: Teva's Austedo drug saw first-quarter sales jump 41% year-over-year to $578 million, driving overall performance improvements and further boosting market confidence.
- Improved Financial Health: As of March 31, 2026, Teva's financial leverage dropped to 67%, and the company expects to realize approximately $470 million in net savings from transformation initiatives, demonstrating proactive efforts in cost-cutting and financial health improvement.
See More
Bank of America Bullish on Multiple Stocks Following Earnings
- Caterpillar Growth Potential: Bank of America analysts noted that Caterpillar's stock has surged over 175% in the past 12 months, raising the price target from $930 to $989, emphasizing its growth potential in high-margin services, which is expected to stabilize future EPS.
- Baker Hughes Financial Performance: Baker Hughes shares have climbed 76% over the past year, with analysts highlighting its unique position at the intersection of energy and industrial markets, suggesting that despite challenges from the Iran conflict, its diversified business mix and strong execution will help maintain a positive medium to long-term growth outlook.
- Apple's Strong Performance: Bank of America analysts labeled Apple as a
See More
Trade Desk Faces Publicis Challenge Amid Earnings Miss
- Publicis Controversy Impact: Trade Desk's Q1 2026 earnings miss led to a 13.11% drop in pre-market trading, primarily due to Publicis's concerns over pricing and transparency, which could result in client losses and significantly impact Q2 and Q3 revenues.
- Margin Pressure: The company targets a full-year adjusted EBITDA margin of 40%, yet reported only 30% in Q1, necessitating substantial revenue growth or aggressive cost control in the second half, with management failing to provide a clear strategy, thus increasing market uncertainty.
- Long-Term Outlook Remains Positive: Despite short-term challenges, Trade Desk's long-term strategies, including open internet principles, retail media, and AI search, remain attractive, with Jeff Green's $150 million stock purchase reflecting confidence in the company's future.
- Cautious Market Reaction: Although Publicis's audit found no issues, the market's response to Trade Desk remains cautious, with heightened investor concerns about future profitability and market share, indicating a strong focus on the company's near-term performance.
See More
Evercore (EVR.US) Director Plans to Sell $6.33 Million in Common Stock, According to Form 144
Stock Sale Announcement: Evercore (EVR.US) Director Altman Roger C intends to sell 20,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
See More
Stock Price Movements of Various Companies
- Regeneron Stock Decline: Regeneron shares fell nearly 6% despite reaffirming its full-year adjusted gross margin forecast of 83% to 84%, while the board authorized a $3 billion share repurchase program, indicating confidence in future growth.
- GE HealthCare Downgrade: GE HealthCare's stock tumbled 12% after it lowered its full-year adjusted earnings forecast to a range of $4.80 to $5 per share, down from $4.95 to $5.15, reflecting significant earnings pressure on the company.
- Brinker International Strong Performance: Brinker International's stock jumped about 13% as its third-quarter adjusted earnings reached $2.90 per share, exceeding the market expectation of $2.86, and the company raised its full-year earnings forecast, showcasing business resilience.
- NXP Semiconductors Surge: NXP Semiconductors saw a nearly 25% stock increase after reporting first-quarter adjusted earnings of $3.05 per share, surpassing analyst expectations of $2.95, with revenue of $3.18 billion also exceeding forecasts, indicating strong market performance.
See More
Evercore Reports Record Q1 2026 Earnings Amid Caution
- Record Performance: Evercore's Q1 adjusted net revenues reached $1.4 billion, doubling year-over-year and setting a new quarterly record, reflecting strong momentum from the second half of 2025, although management cautioned that geopolitical and macroeconomic uncertainties could extend transaction timelines.
- Increased Transaction Activity: The number of large transactions closed in Q1 hit a historical high, attributed to timing shifts of major deals, with management emphasizing the importance of evaluating performance over multiple quarters rather than focusing on single-quarter fluctuations.
- Ongoing Talent Investment: The firm currently has 182 Senior Managing Directors in investment banking, with over 45 ramping up, positioning the company for sustained growth despite high competition for top talent.
- Enhanced Capital Returns: As of March 31, Evercore held nearly $2 billion in cash and investment securities, repurchased 1.9 million shares at an average price of $322, and declared a dividend of $0.89 per share, reflecting a 6% increase from the prior dividend, demonstrating the company's commitment to shareholder returns.
See More
Teva Pharmaceutical Stock Doubles, Analysts Remain Optimistic
- Stock Price Surge: Teva Pharmaceutical's stock has soared over 100% in the past 12 months, reflecting strong market confidence in its recovery, with analysts generally optimistic about its future performance.
- Analyst Ratings Positive: In a survey by S&P Global, 12 out of 13 analysts rated Teva as a 'buy' or 'strong buy', indicating recognition of its potential 11% upside in the market.
- Significant Sales Growth: Teva's Austedo drug saw first-quarter sales jump 41% year-over-year to $578 million, driving overall performance improvements and further boosting market confidence.
- Improved Financial Health: As of March 31, 2026, Teva's financial leverage dropped to 67%, and the company expects to realize approximately $470 million in net savings from transformation initiatives, demonstrating proactive efforts in cost-cutting and financial health improvement.
See More
Bank of America Bullish on Multiple Stocks Following Earnings
- Caterpillar Growth Potential: Bank of America analysts noted that Caterpillar's stock has surged over 175% in the past 12 months, raising the price target from $930 to $989, emphasizing its growth potential in high-margin services, which is expected to stabilize future EPS.
- Baker Hughes Financial Performance: Baker Hughes shares have climbed 76% over the past year, with analysts highlighting its unique position at the intersection of energy and industrial markets, suggesting that despite challenges from the Iran conflict, its diversified business mix and strong execution will help maintain a positive medium to long-term growth outlook.
- Apple's Strong Performance: Bank of America analysts labeled Apple as a
See More
Trade Desk Faces Publicis Challenge Amid Earnings Miss
- Publicis Controversy Impact: Trade Desk's Q1 2026 earnings miss led to a 13.11% drop in pre-market trading, primarily due to Publicis's concerns over pricing and transparency, which could result in client losses and significantly impact Q2 and Q3 revenues.
- Margin Pressure: The company targets a full-year adjusted EBITDA margin of 40%, yet reported only 30% in Q1, necessitating substantial revenue growth or aggressive cost control in the second half, with management failing to provide a clear strategy, thus increasing market uncertainty.
- Long-Term Outlook Remains Positive: Despite short-term challenges, Trade Desk's long-term strategies, including open internet principles, retail media, and AI search, remain attractive, with Jeff Green's $150 million stock purchase reflecting confidence in the company's future.
- Cautious Market Reaction: Although Publicis's audit found no issues, the market's response to Trade Desk remains cautious, with heightened investor concerns about future profitability and market share, indicating a strong focus on the company's near-term performance.
See More
Evercore (EVR.US) Director Plans to Sell $6.33 Million in Common Stock, According to Form 144
Stock Sale Announcement: Evercore (EVR.US) Director Altman Roger C intends to sell 20,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
See More
Stock Price Movements of Various Companies
- Regeneron Stock Decline: Regeneron shares fell nearly 6% despite reaffirming its full-year adjusted gross margin forecast of 83% to 84%, while the board authorized a $3 billion share repurchase program, indicating confidence in future growth.
- GE HealthCare Downgrade: GE HealthCare's stock tumbled 12% after it lowered its full-year adjusted earnings forecast to a range of $4.80 to $5 per share, down from $4.95 to $5.15, reflecting significant earnings pressure on the company.
- Brinker International Strong Performance: Brinker International's stock jumped about 13% as its third-quarter adjusted earnings reached $2.90 per share, exceeding the market expectation of $2.86, and the company raised its full-year earnings forecast, showcasing business resilience.
- NXP Semiconductors Surge: NXP Semiconductors saw a nearly 25% stock increase after reporting first-quarter adjusted earnings of $3.05 per share, surpassing analyst expectations of $2.95, with revenue of $3.18 billion also exceeding forecasts, indicating strong market performance.
See More
Evercore Reports Record Q1 2026 Earnings Amid Caution
- Record Performance: Evercore's Q1 adjusted net revenues reached $1.4 billion, doubling year-over-year and setting a new quarterly record, reflecting strong momentum from the second half of 2025, although management cautioned that geopolitical and macroeconomic uncertainties could extend transaction timelines.
- Increased Transaction Activity: The number of large transactions closed in Q1 hit a historical high, attributed to timing shifts of major deals, with management emphasizing the importance of evaluating performance over multiple quarters rather than focusing on single-quarter fluctuations.
- Ongoing Talent Investment: The firm currently has 182 Senior Managing Directors in investment banking, with over 45 ramping up, positioning the company for sustained growth despite high competition for top talent.
- Enhanced Capital Returns: As of March 31, Evercore held nearly $2 billion in cash and investment securities, repurchased 1.9 million shares at an average price of $322, and declared a dividend of $0.89 per share, reflecting a 6% increase from the prior dividend, demonstrating the company's commitment to shareholder returns.
See More
